EG20672A - Neuroprotective compounds - Google Patents
Neuroprotective compoundsInfo
- Publication number
- EG20672A EG20672A EG6795A EG6795A EG20672A EG 20672 A EG20672 A EG 20672A EG 6795 A EG6795 A EG 6795A EG 6795 A EG6795 A EG 6795A EG 20672 A EG20672 A EG 20672A
- Authority
- EG
- Egypt
- Prior art keywords
- pct
- sec
- date
- neuroprotective compounds
- pub
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- JQQWDYJWDCIVKQ-QUCCMNQESA-N (3r,4s)-3-(4-benzyl-4-hydroxypiperidin-1-yl)-3,4-dihydro-2h-chromene-4,7-diol Chemical compound C1CN([C@H]2[C@H](C3=CC=C(O)C=C3OC2)O)CCC1(O)CC1=CC=CC=C1 JQQWDYJWDCIVKQ-QUCCMNQESA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18947994A | 1994-01-31 | 1994-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG20672A true EG20672A (en) | 1999-11-30 |
Family
ID=22697514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EG6795A EG20672A (en) | 1994-01-31 | 1995-01-28 | Neuroprotective compounds |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5744483A (pl) |
| EP (1) | EP0741724B1 (pl) |
| JP (1) | JP2866743B2 (pl) |
| CN (1) | CN1048247C (pl) |
| AT (1) | ATE183184T1 (pl) |
| AU (1) | AU684568B2 (pl) |
| BR (2) | BR9408506A (pl) |
| CA (1) | CA2182101C (pl) |
| CO (1) | CO4230161A1 (pl) |
| CZ (1) | CZ286757B6 (pl) |
| DE (1) | DE69420053T2 (pl) |
| DK (1) | DK0741724T3 (pl) |
| EG (1) | EG20672A (pl) |
| ES (1) | ES2134361T3 (pl) |
| FI (1) | FI113769B (pl) |
| GR (1) | GR3031356T3 (pl) |
| HU (1) | HU221633B1 (pl) |
| IL (1) | IL112415A (pl) |
| MY (1) | MY111623A (pl) |
| NO (1) | NO309190B1 (pl) |
| NZ (1) | NZ275151A (pl) |
| PE (1) | PE43795A1 (pl) |
| PL (1) | PL179448B1 (pl) |
| RU (1) | RU2126404C1 (pl) |
| TW (1) | TW449591B (pl) |
| WO (1) | WO1995020587A1 (pl) |
| ZA (1) | ZA95692B (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11509839A (ja) * | 1995-09-15 | 1999-08-31 | ファイザー・インコーポレーテッド | 薬剤活性を有するフェノール誘導体 |
| TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| PE20020291A1 (es) * | 2000-08-21 | 2002-04-17 | Hoffmann La Roche | Profarmacos para ligandos del receptor nmda |
| EP1674087A1 (en) | 2000-10-02 | 2006-06-28 | Pfizer Products Inc. | Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists |
| ZA200108038B (en) * | 2000-10-02 | 2003-04-01 | Pfizer Prod Inc | Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists. |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| AU2002355170B2 (en) * | 2001-07-26 | 2007-06-07 | Merck Patent Gmbh | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| RU2240113C1 (ru) * | 2003-01-23 | 2004-11-20 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова | Способ экстренной медикаментозной помощи при острой травме спинного мозга |
| ATE473967T1 (de) * | 2003-11-26 | 2010-07-15 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
| BRPI0618206A2 (pt) | 2005-11-03 | 2011-08-23 | Hoffmann La Roche | arilsulfonil cromanos como inibidores de 5-ht6, bem como composição farmacêutica, uso e processo para produção dos mesmos |
| KR20080095885A (ko) * | 2006-01-20 | 2008-10-29 | 쉐링 코포레이션 | 벤젠설포닐-크로만, 티오크로만, 테트라하이드로나프탈렌 및 관련된 감마 세크라타제 억제제 |
| RU2418578C1 (ru) * | 2009-12-08 | 2011-05-20 | Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | ПРИМЕНЕНИЕ 4,7-ДИМЕТИЛ-2-(ПРОП-1-ЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛА В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА |
| EP2522647B1 (en) * | 2011-05-10 | 2014-04-30 | DSM IP Assets B.V. | Process of separating chiral isomers of chroman compounds and their derivatives and precursors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3294804A (en) * | 1961-01-27 | 1966-12-27 | Sterling Drug Inc | 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
| FR5733M (pl) * | 1966-09-27 | 1968-01-22 | ||
| GB1495526A (en) * | 1974-05-31 | 1977-12-21 | Beecham Group Ltd | Chroman derivatives |
| US4016281A (en) * | 1975-02-22 | 1977-04-05 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Tetralone and indanone compounds |
| US4082755A (en) * | 1977-02-14 | 1978-04-04 | Janssen Pharmaceutica N.V. | 1-[(Diarylmethyl)aminoalkyl]piperidimes |
| WO1980000152A1 (fr) * | 1978-07-03 | 1980-02-07 | Sandoz Ag | Derives d'un 3-aminopropoxy-aryle, leur preparation et utilisation |
| US4358456A (en) * | 1980-05-03 | 1982-11-09 | John Wyeth & Brother Limited | Antipsychotic piperidinomethyl-indole derivatives |
| DE3045688A1 (de) * | 1980-12-04 | 1982-07-08 | C.H. Boehringer Sohn, 6507 Ingelheim | Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung |
| EP0076075B1 (en) * | 1981-09-25 | 1986-11-20 | Beecham Group Plc | Pharmaceutically active benzopyran compounds |
| EP0093534A1 (en) * | 1982-04-28 | 1983-11-09 | Beecham Group Plc | Novel chromanols |
| ES523609A0 (es) * | 1982-07-05 | 1985-03-01 | Erba Farmitalia | Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos. |
| GB8308064D0 (en) * | 1983-03-24 | 1983-05-05 | Beecham Group Plc | Active compounds |
| FR2546166B1 (fr) * | 1983-05-19 | 1985-10-25 | Synthelabo | Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique |
| FR2581993B1 (fr) * | 1985-05-14 | 1988-03-18 | Synthelabo | Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique |
| US4957928A (en) * | 1986-06-26 | 1990-09-18 | Ciba-Geigy Corporation | Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds |
| US4968678A (en) * | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
| FR2640266B2 (fr) * | 1988-07-12 | 1992-07-10 | Synthelabo | Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique |
| US4968878A (en) * | 1989-02-07 | 1990-11-06 | Transitions Research Corporation | Dual bumper-light curtain obstacle detection sensor |
| US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| SK232890A3 (en) * | 1989-05-17 | 1998-11-04 | Pfizer | 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof |
| HU222726B1 (hu) * | 1990-02-06 | 2003-09-29 | Pfizer, Inc., | Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények |
| US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
-
1994
- 1994-11-21 CN CN94194940A patent/CN1048247C/zh not_active Expired - Fee Related
- 1994-11-21 EP EP94931668A patent/EP0741724B1/en not_active Expired - Lifetime
- 1994-11-21 CA CA002182101A patent/CA2182101C/en not_active Expired - Fee Related
- 1994-11-21 NZ NZ275151A patent/NZ275151A/en unknown
- 1994-11-21 CZ CZ19962256A patent/CZ286757B6/cs not_active IP Right Cessation
- 1994-11-21 RU RU96117381A patent/RU2126404C1/ru not_active IP Right Cessation
- 1994-11-21 WO PCT/IB1994/000365 patent/WO1995020587A1/en not_active Ceased
- 1994-11-21 DE DE69420053T patent/DE69420053T2/de not_active Expired - Fee Related
- 1994-11-21 AU AU80663/94A patent/AU684568B2/en not_active Ceased
- 1994-11-21 US US08/687,542 patent/US5744483A/en not_active Expired - Fee Related
- 1994-11-21 HU HU9602100A patent/HU221633B1/hu not_active IP Right Cessation
- 1994-11-21 PL PL94315681A patent/PL179448B1/pl unknown
- 1994-11-21 DK DK94931668T patent/DK0741724T3/da active
- 1994-11-21 BR BR9408506A patent/BR9408506A/pt not_active Application Discontinuation
- 1994-11-21 JP JP7519959A patent/JP2866743B2/ja not_active Expired - Lifetime
- 1994-11-21 ES ES94931668T patent/ES2134361T3/es not_active Expired - Lifetime
- 1994-11-21 AT AT94931668T patent/ATE183184T1/de not_active IP Right Cessation
- 1994-11-22 TW TW083110873A patent/TW449591B/zh active
-
1995
- 1995-01-18 PE PE1995259688A patent/PE43795A1/es not_active Application Discontinuation
- 1995-01-23 IL IL11241595A patent/IL112415A/xx not_active IP Right Cessation
- 1995-01-27 CO CO95003001A patent/CO4230161A1/es unknown
- 1995-01-27 MY MYPI95000224A patent/MY111623A/en unknown
- 1995-01-28 EG EG6795A patent/EG20672A/xx active
- 1995-01-30 BR BR9500380A patent/BR9500380A/pt not_active IP Right Cessation
- 1995-01-30 FI FI950403A patent/FI113769B/fi not_active IP Right Cessation
- 1995-01-30 ZA ZA95692A patent/ZA95692B/xx unknown
-
1996
- 1996-07-30 NO NO963186A patent/NO309190B1/no unknown
-
1999
- 1999-09-29 GR GR990402449T patent/GR3031356T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG20672A (en) | Neuroprotective compounds | |
| HU9502193D0 (en) | Combination treatment for inhibiting bone loss | |
| IL113566A0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
| ZA953701B (en) | New atagonist compounds | |
| IL127044A (en) | Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenertive diseases | |
| IL112288A0 (en) | Application of riluzole in the treatment of mitochondrial diseases | |
| NZ268110A (en) | Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage | |
| EP0653936A1 (en) | USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL] -3-HYDROXY-1,4-NAPHTOQUINONE IN THE TREATMENT OF CANCER. | |
| NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
| RU94044487A (ru) | Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия | |
| BG105289A (en) | The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders | |
| AU2796695A (en) | Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders |